Taysha Gene Therapies Inc (TSHA)

[FooBarAndGrill]

“Dosing the first pediatric patient with Rett syndrome marks an important step forward in our efforts to broaden the clinical evaluation of TSHA-102 to younger patients with earlier stages of Rett syndrome. We are pleased with our progress on expanding the study of TSHA-102 across a broad population of ages and stages of Rett syndrome to bring a potentially transformative treatment option to all patients and families suffering from this devastating disease,” said Sukumar Nagendran, M.D., President, and Head of R&D of Taysha. “The pediatric trial will build on our ongoing REVEAL adolescent and adult trial, where early data demonstrated improvements across multiple clinical domains in adult patients with the most advanced stage of disease. We also plan to expand our U.S. pediatric trial into the U.K. following the recent acceptance of our CTA by the MHRA.”